UbiPharm publications and

market research

UbiPharm's Ethics and Anti-Corruption Charter reflects our unwavering commitment to integrity, transparency and accountability in all our activities. It defines the principles and ethical standards that we undertake to respect and promote within our organisation and with our partners.

By adhering to these guidelines, we reinforce our mission to ensure the reliable and ethical distribution of pharmaceutical products in Africa and the French overseas departments and regions.

We invite all our stakeholders to consult this charter, rigorously apply these principles and actively commit to a fair working environment.

The UbiPharm Group, supply chain experts in Africa and the French overseas departments and territories, announces the publication of the Company's 2023 Extra-Financial Performance Declaration (DPEF).

This report highlights our commitments and achievements in terms of sustainable development, social responsibility and governance. It reflects our ongoing commitment to promoting ethical and transparent practices in the distribution of pharmaceutical products in Africa and the French territories.

We invite you to consult the DPEF 2023 to find out more about our initiatives and our positive impact on the communities we serve.

The UbiPharm group, a pan-African expert in logistics and the pharmaceutical supply chain in Africa and the French overseas territories, publishes its extra-financial performance statement (Déclaration de Performance Extra-Financière - DPEF - in French ) for the 2022 financial year illustrating its social responsibility.

The extra-financial performance declaration, also called DPEF, is published annually and gives stakeholders a vision of the CSR performance of the UbiPharm group. The latter reports on the policies implemented by the Group regarding environmental and societal issues.